NFKB1 and lymphoma: However, efforts to produce a clinically compatible NIK inhibitor are ongoing and not only for treatment of rare lymphomas such as AITL, but also for melanomas and other cancers, which are strongly addicted to the noncanonical NF-κB pathway145.